The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients

Wang, Yukun; Liu, Zixuan; Zhou, Zhonghua; Rao, Hanyu; Xiong, Jie; Xie, Shuanshuan

doi:10.7150/jca.86495



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2023; 14(11):2093-2108. doi:10.7150/jca.86495 This issue Cite

Research Paper

The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients

Yukun Wang^1,2,#, Zixuan Liu^1,2,#, Zhonghua Zhou^3,#, Hanyu Rao^1,2, Jie Xiong^3,✉, Shuanshuan Xie^1,3,✉

1. Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University; Shanghai 200040, China.
2. Tongji University School of Medicine; Shanghai 200072, China.
3. Department of Respiratory Medicine, ChongMing Branch of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 202150, China.
#These authors have contributed equally to this work.

Citation:

Wang Y, Liu Z, Zhou Z, Rao H, Xiong J, Xie S. The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients. J Cancer 2023; 14(11):2093-2108. doi:10.7150/jca.86495. https://www.jcancer.org/v14p2093.htm

Other styles

Abstract

Background: Regional lymph nodes (RLNs) removed combined with surgery is a standard option for patients at stage I to IIIA NSCLC. The objective of the study is to clarify the effect of removing different number of RLNs on survival outcomes for patients at stage IIIA N0 NSCLC.

Methods: Patients at stage IIIA N0 NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Prior propensity score method (PSM), survival time was compared among different number (0, 1-3 and ≥4) of RLNs removed groups. After PSM, lung cancer-specific survival (LCSS) and overall survival (OS) were compared. Kaplan-Meier analysis and Cox regression analyses were used to clarify the impact of the factors on the prognosis with hazard ratio (HR) and 95% confidence interval (CI).

Results: A total of 11,583 patients at stage IIIA N0 NSCLC were included. Prior PSM, survival indicators including 1-year mortality rate, 5-year mortality rate, median survival time (MDST) and mean survival time (MST) from good to bad were all: ≥4, 1-3 and none RLNs removed group. After PSM, Kaplan-Meier survival analyses and univariate Cox regression analyses on OS and LCSS revealed a statistically significance on survival curve (P<0.001) between each two of the three groups (none, 1-3 and ≥4 RLNs removed group). Multivariable Cox regression analyses on OS and LCSS showed an independent association of RLNs removed with higher OS (HR, 0.275; 95% CI, 0.259-0.291; P<0.001) and LCSS (HR, 0.239; 95% CI, 0.224-0.256; P<0.001) compared with none RLN removed and no statistical difference with OS (HR, 1.118; 95% CI, 0.983-1.271; P=0.088) and LCSS (HR, 1.107; 95% CI, 0.954-1.284; P=0.179) between 1-3 RLNs removed and ≥4 RLNs removed.

Conclusions: Removing RLNs was beneficial to survival outcomes of patients at stage IIIA N0 NSCLC. Compared with 1-3 RLNs removed, ≥4 RLNs removed could bring a better survival time but not an independent prognostic factor (P>0.05).

Keywords: regional lymph nodes, non-small cell lung cancer, lung cancer-specific survival, overall survival

Citation styles

APA

Wang, Y., Liu, Z., Zhou, Z., Rao, H., Xiong, J., Xie, S. (2023). The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients. Journal of Cancer, 14(11), 2093-2108. https://doi.org/10.7150/jca.86495.

ACS

Wang, Y.; Liu, Z.; Zhou, Z.; Rao, H.; Xiong, J.; Xie, S. The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients. J. Cancer 2023, 14 (11), 2093-2108. DOI: 10.7150/jca.86495.

NLM

CSE

Wang Y, Liu Z, Zhou Z, Rao H, Xiong J, Xie S. 2023. The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients. J Cancer. 14(11):2093-2108.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.